Almirall SA, of Barcelona, Spain, said the European Commission granted marketing approval to Eklira/Bretaris Genuair (aclidinium 322 mcg twice daily) in European Union member states, plus Iceland and Norway, for chronic obstructive pulmonary disease...Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the European Commission granted marketing authorization to Jentadueto (linagliptin/metformin hydrochlorid) in Type II diabetes

Mundipharma International Ltd., of Cambridge, UK, said the European Commission approved combination therapy flutiform (fluticasone propionate/formoterol fumarate) for the maintenance treatment of asthma

Full European Commission approval is anticipated in three months

If approved by the European Commission, the drug would offer a single-tablet treatment option, taken twice-daily, for adults with Type II diabetes who need to improve control of their blood glucose

The European Commission generally follows CHMP recommendations and usually delivers its final decision within three months

The European Commission approved Halaven on March 17, 2011

Baxter International Inc., of Deerfield, Ill., said the European Commission granted marketing authorization of Vepacel, a pre-pandemic influenza vaccine indicated for active immunization in adults, ages 18 and older, against the H5N1 subtype of influenza A. The label includes use in immunocompromised and chronically ill patients

The European Commission's decision is expected shortly

A final decision from the European Commission is anticipated in a few weeks